HTL0046509
Ulcerative Colitis
Key Facts
About Nxera Pharma
Nxera Pharma is a Tokyo-based, publicly traded biopharmaceutical company with a mission to deliver transformative medicines by exploiting its proprietary expertise in G protein-coupled receptor (GPCR) structure-based drug design. The company has successfully evolved from a technology licensing model into a robust, pipeline-driven enterprise with 16+ assets, underpinned by its StaR® technology platform and a dual-hub operational model spanning Japan and the UK. Its strategy focuses on advancing internal neuroscience and immuno-oncology candidates while generating significant value through strategic partnerships with major global pharmaceutical companies, positioning it as a key player in the next generation of GPCR-targeted therapeutics.
View full company profileTherapeutic Areas
Other Ulcerative Colitis Drugs
| Drug | Company | Phase |
|---|---|---|
| PALI-2108 | Palisade Bio | Phase 2 |
| ALTB-268 | AltruBio | Phase IIa |
| AIM-HI-UC | PathAI | Clinical Trials |
| Patient Stratification in Ulcerative Colitis | Enable Medicine | Research |
| Mesalazine (Lifecycle Management) | Dr. Falk Pharma | Approved/Phase 3 |
| AhR Agonist Program | Azora Therapeutics | Phase 1b |
| R-3750 | Virtici | Phase 1 |
| GPR35 Inhibitor | ThirtyFiveBio | Preclinical |
| BEN-8744 | BenevolentAI | Phase 1b |
| BT-600 | Biora Therapeutics | Phase 1 |
| Asacol® (mesalazine) | Tillotts Pharma | Approved |
| MB310 | Microbiotica | Phase 1b |